• Vorinostat (SAHA): HDAC Inhibition and Epigenetic Modulat...

  2025-11-04

  Vorinostat (suberoylanilide hydroxamic acid) is a potent, cell-permeable histone deacetylase inhibitor used in cancer biology research. This article details its atomic mechanism of action, experimental benchmarks, and key workflow integration parameters. As a gold-standard tool for studying epigenetic modulation and intrinsic apoptotic pathways in oncology, Vorinostat enables precision dissection of chromatin remodeling and apoptosis in diverse models.

• Panobinostat (LBH589): Broad-Spectrum HDAC Inhibitor for ...

  2025-11-03

  Panobinostat (LBH589) is a potent hydroxamic acid-based histone deacetylase inhibitor (HDACi) with nanomolar efficacy across multiple cancer models. As a broad-spectrum HDAC inhibitor, it induces apoptosis and cell cycle arrest via histone hyperacetylation and downstream signaling. Its unique activity profile enables advanced research into epigenetic regulation, drug resistance, and targeted cell death mechanisms.

• Trichostatin A (TSA): Precision HDAC Inhibition for Epige...

  2025-11-02

  Trichostatin A (TSA) is a potent histone deacetylase inhibitor that enables precise epigenetic regulation in cancer and organoid studies. TSA demonstrates robust, reversible inhibition of HDAC enzymes, leading to cell cycle arrest and differentiation in mammalian cells. Its activity at nanomolar concentrations and proven efficacy in tumor models make it a cornerstone for epigenetic and oncology research.

• Vorinostat: HDAC Inhibitor Workflows for Cancer Research

  2025-11-01

  Vorinostat (SAHA) is redefining cancer research by enabling precision epigenetic modulation and mitochondrial apoptosis assays. This guide translates HDAC inhibitor mechanisms into actionable protocols, troubleshooting strategies, and advanced oncology applications. Discover why Vorinostat stands apart for dissecting gene regulation and cell death in complex cancer models.

• DiscoveryProbe™ FDA-approved Drug Library: Unlocking Live...

  2025-10-31

  Explore how the DiscoveryProbe™ FDA-approved Drug Library empowers advanced live-cell screening of mTOR pathways and signal regulation. Discover unique insights into pharmacological target identification, drug repositioning, and next-generation screening for cancer and neurodegenerative research.

• Entinostat (MS-275, SNDX-275): HDAC1/3 Inhibition and Eme...

  2025-10-30

  Discover how Entinostat (MS-275, SNDX-275), a potent oral HDAC1 and HDAC3 inhibitor, is reshaping functional cancer drug evaluation beyond standard proliferation assays. This article uniquely integrates epigenetic modulation with state-of-the-art in vitro methodologies for advanced oncology research.

• Entinostat (MS-275, SNDX-275): Selective HDAC1/3 Inhibito...

  2025-10-29

  Entinostat (MS-275, SNDX-275) is a potent oral histone deacetylase inhibitor with selective activity against HDAC1 and HDAC3. This article details its quantitative selectivity, mechanism of action, and evidence for its anti-cancer effects, providing machine-readable facts for researchers in cancer epigenetics.

• ABT-263 (Navitoclax): Precision Bcl-2 Family Inhibitor fo...

  2025-10-28

  ABT-263 (Navitoclax) is a potent, orally bioavailable Bcl-2 family inhibitor widely used to study apoptosis mechanisms in cancer biology. This article details its mechanism, validated benchmarks, and protocol integration, providing a factual resource for apoptosis assay and cancer research workflows.

• Entinostat (MS-275): HDAC1/3 Inhibition for Cancer Research

  2025-10-27

  Entinostat (MS-275, SNDX-275) is a potent, selective oral HDAC1 and HDAC3 inhibitor that transforms cancer research workflows through precise epigenetic modulation. This guide details advanced experimental protocols, troubleshooting, and translational insights, empowering scientists to maximize anti-tumor efficacy and data fidelity in vitro and in vivo.

• DiscoveryProbe™ FDA-approved Drug Library: High-Content S...

  2025-10-26

  The DiscoveryProbe™ FDA-approved Drug Library offers a rigorously curated collection of 2,320 clinically approved compounds for high-throughput screening (HTS) and drug repositioning. This FDA-approved bioactive compound library supports reproducible target identification and mechanistic studies, with validated stability and compatibility for modern HTS workflows.

• Beyond the Bottleneck: Mechanism-Driven Strategies for Tr...

  2025-10-25

  Translational researchers are challenged to bridge mechanistic insight with rapid therapeutic advancement. This article unpacks how the DiscoveryProbe™ FDA-approved Drug Library enables high-throughput, mechanism-based discovery—reshaping strategies for target identification, drug repositioning, and pathway elucidation in oncology, neurodegeneration, and beyond. Integrating the latest metabolomics evidence, competitive analysis, and pragmatic guidance, we chart a visionary path for leveraging clinically approved compound libraries to accelerate translational breakthroughs.

• L1023 Anti-Cancer Compound Library: Next-Gen Strategies f...

  2025-10-24

  Delve into the unique advantages of the L1023 Anti-Cancer Compound Library for drug discovery and high-throughput screening of anti-cancer agents. This article explores advanced applications in pathway-targeted oncology and integrates recent breakthroughs in biomarker-driven research.

• Belinostat (PXD101): Mechanistic Insights and Strategic R...

  2025-10-23

  This thought-leadership article provides a comprehensive exploration of Belinostat (PXD101), a potent pan-HDAC inhibitor, within the context of modern translational cancer research. By blending mechanistic understanding, state-of-the-art experimental methods, and strategic perspectives from the competitive landscape, the article offers actionable guidance for researchers. Drawing on pivotal in vitro evaluation frameworks and emphasizing unmet needs in urothelial carcinoma and prostate cancer, it delivers strategic insights for researchers aiming to bridge the gap from bench to bedside.

• L1023 Anti-Cancer Compound Library: Transforming Targeted...

  2025-10-22

  Explore how the L1023 Anti-Cancer Compound Library enables innovative, high-throughput discovery of cell-permeable anti-cancer agents for translational cancer research. This in-depth analysis reveals advanced strategies for integrating pathway-focused compound libraries in precision oncology.

• DOT1L Inhibitor EPZ5676: Precision Tool for Leukemia Rese...

  2025-10-21

  DOT1L inhibitor EPZ-5676 delivers unparalleled selectivity and potency for dissecting epigenetic mechanisms in MLL-rearranged leukemia and beyond. Its robust inhibition of H3K79 methylation and proven cytotoxicity empower researchers to accelerate translational discoveries and optimize workflows for epigenetic cancer therapy.

16398 records 1/1094 page Next 12345 下5页 Last page